CHI3L1, chitinase 3 like 1, 1116

N. diseases: 420; N. variants: 9
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 AlteredExpression disease BEFREE In summary, the differential expression of the immunomodulatory molecule YKL-40 may affect the treatment efficacy of PI3K/AKT-based pathway inhibitors in glioblastoma. 29729901 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Previous studies have demonstrated that glioblastoma stem cells give rise to endothelial cells through an YKL-40 influence. 28430288 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 PosttranslationalModification disease BEFREE Phospho-c-Jun activation by Anisomycin treatment in primary glioblastoma-derived cells attenuates the aggressive features of mesenchymal glioblastomas and leads to promoter methylation and downregulation of key mesenchymal genes (CD44, MMP9 and CHI3L1). 28036297 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression disease BEFREE Meta-analysis of those studies showed that high YKL-40 expression was associated with worse overall survival in glioblastoma patients (HR = 1.46, 95%CI 1.33-1.61, P < 0.001). 27090900 2017
CUI: C0017638
Disease: Glioma
Glioma
0.400 Biomarker disease BEFREE These results suggest that the STAT3 pathway is associated with the mTOR downstream pathway mediated by YKL-40 protein, and the combination therapy of the STAT3 inhibitor and rapamycin could be worth developing as a novel therapeutic approach against TMZ-resistant relapsed gliomas. 28031240 2017
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 AlteredExpression disease BEFREE Meta-analysis of those studies showed that high YKL-40 expression was associated with worse overall survival in glioblastoma patients (HR = 1.46, 95%CI 1.33-1.61, P < 0.001). 27090900 2017
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 Biomarker disease BEFREE Previous studies have demonstrated that glioblastoma stem cells give rise to endothelial cells through an YKL-40 influence. 28430288 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression disease BEFREE Findings presented in our study showed that increased mRNA level of CHI3L1 could be associated with the progression of astrocytoma and poor patient survival not only for glioblastoma, but for lower grade astrocytoma tumors as well. 27121858 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Both our case reports were adult males who developed extra-CNS, YKL-40-positive metastases at lymph nodes, lung and subcutaneous sites, after 86 and 24 months from initial diagnosis of GBM. 26212701 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Stepwise multivariate Cox proportional hazards models were used, and the prognostic factors to significantly impact OS were: PFS < 54 weeks (HR: 5.86; CI: 3.02-11.33; p = 0.00); radiotherapy (HR: 0.34; CI: 0.18-0.60; p = 0.00); radio- and chemotherapy (HR: 0.05; CI: 0.03-0.10; p = 0.0), and YKL-40+ GBs (HR: 1.61; CI: 1.28-2.31; p = 0.01). 27179219 2016
CUI: C0017638
Disease: Glioma
Glioma
0.400 AlteredExpression disease BEFREE We measured CHI3L1 expression with quantitative real time-polymerase chain reaction (qRT-PCR) in the cohort of 98 patients with different grade glioma: 10 grade I pylocytic astrocytomas, 30 grade II diffuse astrocytomas, 20 grade III anaplastic astrocytomas, and 38 grade IV astrocytomas (glioblastomas). 27121858 2016
CUI: C0017638
Disease: Glioma
Glioma
0.400 Biomarker disease BEFREE The aim of this study was to investigate, in a small series of three GCAs, the expression of mesenchymal/radioresistance-associated biomarkers [such as chitinase-3-like protein 1 (YKL-40), hepatocyte growth factor receptor (c-Met), and caveolin 1 (Cav1)] that could contribute to the poor outcome associated with this glioma subgroup. 26845757 2016
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 Biomarker disease BEFREE Both our case reports were adult males who developed extra-CNS, YKL-40-positive metastases at lymph nodes, lung and subcutaneous sites, after 86 and 24 months from initial diagnosis of GBM. 26212701 2016
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 Biomarker disease BEFREE Beyond known key players for GBM such as ERBB2, PMS2, or CHI3L1, we identified over 50 genes that have not been associated to GBM so far. 25537509 2015
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Therefore, YKL‑40 may be a novel key molecule in addition to MGMT, that is responsible for TMZ resistance in glioblastoma cell lines and could be a new target to overcome TMZ resistance in recurrent glioblastomas in the future. 24842123 2014
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE YKL-40 staining in situ was more abundant in glioblastoma tissue than in anaplastic astrocytoma, with the lowest level in normal brain tissue. 25629266 2014
CUI: C0017638
Disease: Glioma
Glioma
0.400 AlteredExpression disease BEFREE Our gene analysis revealed that in general, YKL40 mRNA in glioma patients was over-expressed versus normal brain. 25629266 2014
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 Biomarker disease BEFREE YKL-40 staining in situ was more abundant in glioblastoma tissue than in anaplastic astrocytoma, with the lowest level in normal brain tissue. 25629266 2014
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 Biomarker disease BEFREE Therefore, YKL‑40 may be a novel key molecule in addition to MGMT, that is responsible for TMZ resistance in glioblastoma cell lines and could be a new target to overcome TMZ resistance in recurrent glioblastomas in the future. 24842123 2014
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression disease BEFREE In this paper, the authors' goal was to evaluate the prognostic value of YKL-40 expression as a prognostic factor for glioblastomas and to compare its validity to the already known MGMT. 22655594 2012
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Fitting models with and without YKL-40 highlights a subgroup of patients who have glioblastoma (GBM) diagnosis but appear to have better prognosis than the typical GBM patient. 22495652 2012
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 Biomarker disease BEFREE Fitting models with and without YKL-40 highlights a subgroup of patients who have glioblastoma (GBM) diagnosis but appear to have better prognosis than the typical GBM patient. 22495652 2012
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression disease BEFREE YKL-40 up-regulated VEGF expression in glioblastoma cell line U87, and both YKL-40 and VEGF synergistically promote endothelial cell angiogenesis. 21385870 2011
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression disease BEFREE Although YKL-40 expression is up-regulated in glioblastoma multiforme, its regulation and functions in nontransformed cells of the central nervous system are widely unexplored. 21953450 2011
CUI: C0017638
Disease: Glioma
Glioma
0.400 Biomarker disease CTD_human Thus, targeting the CHI3L1 molecule may be a potential therapeutic molecular target for gliomas. 20506295 2011